Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» breast cancer
breast cancer
AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment
AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment
BioSpace
AstraZeneca
Truqap
breast cancer
Flag link:
FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer
FDA Approves Truqap Plus Faslodex for Advanced HR-Positive Breast Cancer
Pharm Exec
AstraZeneca
Truqap
breast cancer
HR-positive
Flag link:
Olema scores in Phase II breast cancer trial with Phase III dosing in weeks
Olema scores in Phase II breast cancer trial with Phase III dosing in weeks
Clinical Trials Arena
Olema
clinical tirals
palazestrant
breast cancer
Flag link:
Seagen wins future royalties in Enhertu patent dispute
Seagen wins future royalties in Enhertu patent dispute
Pharmaphorum
Seagen
Daiichi Sankyo
breast cancer
Enhertu
drug royalties
Flag link:
BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC
BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC
Fierce Biotech
BioNTech
Daiichi Sankyo
antibody-drug conjugate
breast cancer
Flag link:
Daiichi Sankyo reports positive results from trial of breast cancer therapy
Daiichi Sankyo reports positive results from trial of breast cancer therapy
Clinical Trials Arena
Daiichi Sankyo
clinical trials
Dato-DXd
breast cancer
Flag link:
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
BioSpace
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Flag link:
Seagen’s breast cancer therapy meets main goal in late-stage study
Seagen’s breast cancer therapy meets main goal in late-stage study
Medical Marketing and Media
Seagen
Tukysa
breast cancer
clinical trials
Flag link:
Merck's Keytruda meets main goal in late-stage breast cancer study
Merck's Keytruda meets main goal in late-stage breast cancer study
Reuters
Merck
Keytruda
clinical trials
breast cancer
Flag link:
ASCO in Review: Oncologists See Practice-Changing, Affirming Data
ASCO in Review: Oncologists See Practice-Changing, Affirming Data
BioSpace
ASCO 2023
oncologists
cancer
AstraZeneca
Tagrisso
non-small cell lung cancer
Novartis
Kisqali
breast cancer
Merck
Keytruda
Moderna Therapeutics
cancer vaccine
Flag link:
Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment
Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment
BioSpace
Burning Rock Biotech
genomic profiling
OncoScreen Plus
breast cancer
Medtech
diagnostics
Flag link:
Novartis drug helps stop breast cancer’s return in large study
Novartis drug helps stop breast cancer’s return in large study
BioPharma Dive
Novartis
Kisqali
clinical trials
breast cancer
Flag link:
Byondis' breast cancer drug fails to bloom as FDA denies approval
Byondis' breast cancer drug fails to bloom as FDA denies approval
Fierce Biotech
Byondis
antibody-drug conjugate
FDA
breast cancer
HER-2 positive breast cancer
Flag link:
Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect
Roche, with HER2 franchise under pressure, pays $70M for breast cancer brain metastases prospect
Fierce Biotech
Roche
Zion Pharma
brain metastases
breast cancer
Flag link:
Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec
Roche nixes Tecentriq trial in early breast cancer, but it's 'still in the game' in key lung cancer use: exec
Fierce Pharma
Roche
Tecentriq
breast cancer
Teresa Graham
Pharma CEOs
Flag link:
OncoRix's breast cancer integrative solution demonstrated enhanced efficacy when combined with chemotherapy in an ex-vivo model
OncoRix's breast cancer integrative solution demonstrated enhanced efficacy when combined with chemotherapy in an ex-vivo model
BioSpace
OncoRix
breast cancer
oncology
Flag link:
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
Novartis' Kisqali cuts recurrence risk in early-stage breast cancer
BioSpace
Novartis
clinical trials
Kisqali
breast cancer
Flag link:
Olema Oncology to cut 25% of staff, says it will focus on late-stage pipeline
Olema Oncology to cut 25% of staff, says it will focus on late-stage pipeline
Endpoints
Olema Oncology
breast cancer
layoffs
OP-1250
Flag link:
FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands
FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands
Fierce Pharma
Eli Lilly
Verzenio
breast cancer
Flag link:
Aileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924
Aileron Terminates Phase 1b Breast Cancer Chemoprotection Trial Of ALRN-6924
NASDAQ
Aileron Therapeutics
clinical trials
breast cancer
ALRN-6924
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »